Matthew Ronsheim
Corporate Officer/Principal chez ENTASIS THERAPEUTICS HOLDINGS INC.
Fortune : 607 245 $ au 30/04/2024
Profil
Matthew Ronsheim is currently the Chief Pharmaceutical Sciences Officer at Entasis Therapeutics Holdings, Inc. Prior to this, he was the Executive Director & Head-Chemistry Manufacturing at Enanta Pharmaceuticals, Inc. from 2016 to 2019.
He received his undergraduate degree from Southern Connecticut State University and his doctorate from the University of New Hampshire.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INNOVIVA, INC.
0,06% | 20/05/2024 | 40 510 ( 0,06% ) | 607 245 $ | 30/04/2024 |
Postes actifs de Matthew Ronsheim
| Sociétés | Poste | Début |
|---|---|---|
| ENTASIS THERAPEUTICS HOLDINGS INC. | Corporate Officer/Principal | 01/09/2020 |
Anciens postes connus de Matthew Ronsheim
| Sociétés | Poste | Fin |
|---|---|---|
| ENANTA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/08/2019 |
Formation de Matthew Ronsheim
| Southern Connecticut State University | Undergraduate Degree |
| University of New Hampshire | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
